{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059484","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2026-05-12T21:01:51+00:00","discovered_at":"2026-05-12T21:04:00.412098+00:00","generated_at":"2026-05-12T21:05:02.175927+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"AbbVie shareholders re-elect all Class II directors; reject supermajority elimination and independent chair proposal","bullets":["All four Class II directors elected: Davis (1.22B for), Meyer (1.28B), Michael (1.22B), Waddell (1.23B).","Ratification of EY as auditor approved with 1.52B votes for, 23.8M against.","Advisory say-on-pay approved with 1.23B for, 69.3M against.","Proposal to eliminate supermajority voting did not pass: 1.29B for (needed supermajority).","Stockholder proposal for independent chair rejected: 515.6M for, 787.3M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059484","json":"https://secwatch.observer/filing/0001104659-26-059484.json","markdown":"https://secwatch.observer/filing/0001104659-26-059484.md","text":"https://secwatch.observer/filing/0001104659-26-059484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/tm2614276d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:05:02.175927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18058f93b0794b1160ca1e0a58bbd931c6837af6","claim":"AbbVie Inc. shareholders approved The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026 at the 2026-05-08 meeting.","evidence_excerpt":"The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows: For Against Abstain 1,522,575,012 23,766,564 2,136,457","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"4dc369b0fdd5d95fa1a3d38f6d57da32ec416750","claim":"AbbVie Inc. shareholders rejected The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting at the 2026-05-08 meeting.","evidence_excerpt":"The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,290,990,023 14,896,119 3,192,310 239,399,581","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"6906492ecf515d2b91d92870ace2f5e3148e04b1","claim":"AbbVie Inc. shareholders rejected The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair at the 2026-05-08 meeting.","evidence_excerpt":"The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows: For Against Abstain Broker Non-Votes 515,626,009 787,253,970 6,198,473 239,399,581","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"c53b81e69319a1f72c6c2c647d828d4bbbd6c534","claim":"AbbVie Inc. shareholders approved The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers at the 2026-05-08 meeting.","evidence_excerpt":"The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes 1,228,615,745 69,336,359 11,126,348 239,399,581","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"},{"claim_id":"c9195ed253f88b823665e4342ad624cfe7b02012","claim":"AbbVie Inc. shareholders approved The stockholders elected AbbVie’s Class II directors with terms expiring in 2029 at the 2026-05-08 meeting.","evidence_excerpt":"The stockholders elected AbbVie’s Class II directors with terms expiring in 2029, as follows: Name For Against Abstain Broker Non-Votes Jennifer L. Davis 1,216,558,754 89,839,329 2,680,369 239,399,581 Melody B. Meyer 1,284,771,578 22,470,074 1,836,800 239,399,581 Robert A. Michael 1,221,224,370 85,865,852 1,988,230 239,399,581 Frederick H. Waddell 1,225,237,825 81,747,033 2,093,594 239,399,581","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926059484/0001104659-26-059484-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}